Neuroimmunology in Clinical Practice - part 9 pot
Neuroimmunology in Clinical Practice - part 9 pot
... solution using the
same manufacturing method was licensed in 199 2.
Solvent detergent treatment, including partitioning
steps and incubation at low pH in the final container
has been effective in the ... perivascular
in ammation of the adventitia, and intimal prolifera-
tion resulting in narrowing of arterial lumina. Later
investigators (Kernohan and Woltman, 193 8) sum-
marized the...
Neuroimmunology in Clinical Practice - part 4 pot
... of sinovenous throm-
bosis (Apak et al., 199 9; Atlas et al., 198 6; Baum
et al., 199 4; Caldemeyer et al., 199 4; Cusmai et al.,
199 4; Dale et al., 2000; Hasegawa, 2001; Hesselink
et al., 198 6; ... monophasic and 68% in the relaps-
ing group (Wingerchuck et al., 199 9).
Predictors of relapsing course included longer
interattack intervals between the first two clinical
(index) events,...
Neuroimmunology in Clinical Practice - part 5 potx
... al., 199 1; Finsterer
and Derfler, 199 9; Thomas et al., 199 6).
Studies of rituximab, a monoclonal antibody
against the B-cell marker CD20, have been promis-
ing (Levine and Pestronk, 199 9).
Peripheral ... al., 199 9; Mygland and Monstad,
2001). The prevalence in 70– 7 9- year-old males is
1 in 10,000. The incidence in one study was 0.15/
100,000 (McLeod et al., 199 9). These are like...
Neuroimmunology in Clinical Practice - part 1 ppt
... Gardinier, 199 6; Pham-Dinh et al.,
199 5a; Pham-Dinh et al., 199 5b).
MOG is a type I transmembrane glycoprotein
and is an IgSF member (Ballenthin and Gardinier,
199 6; Kroepfl et al., 199 6). The function ... major dense lines by interacting electro-
statically with the negatively charged headgroups
of myelin lipids (Giese et al., 199 2; Martini et al.,
199 5a; Martini et al., 199 5b),...
Neuroimmunology in Clinical Practice - part 2 pdf
... Drug Administration (FDA) in 199 3 (The
IFNB Multiple Sclerosis Study Group, 199 3). Since
then, the methodology of designing, monitoring,
and interpreting clinical trials has itself evolved into
a ... immune-privileged compart-
ments (reviewed in Abraham, 199 1; Mugnaini and
Schnapp, 197 4). Thus, spermatocyte- and myelin-
specific proteins that are not expressed in the peri-
natal pe...
Neuroimmunology in Clinical Practice - part 3 pdf
... anti-CD40L/-CD154 (IDEC-131); anti-IL-12,
anti-CD6; anti-CD3 (OKT3); anti-Vβ5.2/5.3
+
T cells; anti-CD4; integrin inhibitors
Lymphocyte-specific cytoplasmic protein – tyrosine kinase P56lck; zeta-associated
protein ... used in clinical routine practice should
operate at a field strength higher than 1.0T. With
the introduction of 3T MRI systems into clinical
practice, several questions...
Neuroimmunology in Clinical Practice - part 6 pdf
... Karpati, G. 199 6. Chronic in ammatory demy-
elinating polyneuropathy (CIDP) in diabetics. J
Neurol Sci, 142, 59 64.
Sumner, A.J. 199 4. Electrophysiology of the in am-
matory demyelinating polyneuropathies. ... immunoglobulin in IgM paraprotein asso-
ciated demyelinating neuropathy. J Neurol, 2 49,
1370–7.
Cornblath, D.R. 199 1. Research criteria for diagnosis
of chronic in ammatory...
Neuroimmunology in Clinical Practice - part 7 pps
... T-helper cells by inhibit-
ing calcineurin. While a controlled, double-blind
clinical trial has shown its effectiveness in MG
(Tindell et al., 199 3), significant side effects and drug
interactions ... and
Chastang, C. 199 7. Clinical trial of plasma exchange
and. high-dose intravenous immunoglobulin in
myasthenia gravis. Myasthenia Gravis Clinical Study
Group. Ann Neurol, 41, 7 89 9...
Neuroimmunology in Clinical Practice - part 8 ppt
... GluR1
AGNA-1; ANNA-1,2,3; PCA-2; Ma2; CRMP-5; VGCC
(P/Q>N-type)
Amphiphysin
CRMP-5; ANNA-1; 2, PCA-2
CRMP-5; recoverin
CRMP-5; VGCC; amphiphysin; ganglionic AChR; VGKC;
ANNA-1,2
ANNA-1; CRMP-5; ... blocked
acetylcholine-induced increase in intracellular free
calcium and inhibited
125
I-α-bungarotoxin bind-
ing in cells expressing α7nAChR. The authors
postulate that these antibodies...
Neuroimmunology in Clinical Practice - part 10 pps
... diagnosis 90
first disease bout 93
hyper-recurrent 99 –100
imaging studies 95 –6
infections associated with 91
laboratory tests 94 –5, 94
possible forms of 108
prognosis 97 –8
recurrent 98 9, 99
related ... vasculopathy
230–1
innate immunity 3
interferon-gamma 5
internodal proteins 13–17
CD9 13
myelin-associated glycoprotein
13–14
myelin-associated oligodendrocyte
basic protein...
Từ khóa: